Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering

Murphy, William L.; Peters, Martin C.; Kohn, David H.; Mooney, David J.

doi:10.1016/s0142-9612(00)00120-4

Cited by 385 publications

(221 citation statements)

References 31 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Recent developments in bioengineering scaffold design have led to growth factors to be incorporated onto or entrapped within the scaffolds. (Murphy et al, 2000;Murphy et al, 2004;Yang et al, 2004;Huang et al, 2005a;Huang et al, 2005b;Jansen et al, 2005;Kaigler et al, 2006a;Leach et al, 2006;Oest et al, 2007;Jeon et al, 2007;Kanczler et al, 2007;Wei et al, 2007;Tai et al, 2007;Chang et al, 2007). As these scaffolds are biodegradable, bioactive factors can be released locally over a period of time.…”

Section: Skeletal Tissue Engineering the Clinical Need For New Bonementioning

confidence: 99%

Osteogenesis and angiogenesis: The potential for engineering bone

Kanczler

Oreffo²

2008

eCM

871

637

View full text Add to dashboard Cite

The repair of large bone defects remains a major clinical orthopaedic challenge. Bone is a highly vascularised tissue reliant on the close spatial and temporal connection between blood vessels and bone cells to maintain skeletal integrity. Angiogenesis thus plays a pivotal role in skeletal development and bone fracture repair. Current procedures to repair bone defects and to provide structural and mechanical support include the use of grafts (autologous, allogeneic) or implants (polymeric or metallic). These approaches face significant limitations due to insufficient supply, potential disease transmission, rejection, cost and the inability to integrate with the surrounding host tissue.

show abstract

Section: Skeletal Tissue Engineering the Clinical Need For New Bonementioning

confidence: 99%

Osteogenesis and angiogenesis: The potential for engineering bone

Kanczler

Oreffo²

2008

eCM

871

637

View full text Add to dashboard Cite

show abstract

“…Several researchers have utilized this well-characterized copolymer for encapsulation and release of a wide variety of bioactive molecules and drugs including TGF-b, BMPs, IGFs, VEGF, NGF, DNA, vancomycin, gentamysin, cisplatin, and others. [261][262][263][264][265][266][267][268] To successfully fabricate and encapsulate PLGA scaffold with these molecules, a wide variety of creative approaches have been taken such as emulsion freeze-drying, 269 nano and microparticle encapsulation, [270][271][272] double emulsion solvent extraction, 273 electrospinning, [274][275][276] compression molding, 277 and others. As mentioned earlier, a fundamental problem with utilizing growth factors is their characteristic short half life in physiological environments.…”

Section: Common Copolymers In Bone Engineeringmentioning

confidence: 99%

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Porter

Ruckh

Popat

2009

Biotechnology Progress

564

499

View full text Add to dashboard Cite

Critical‐sized defects in bone, whether induced by primary tumor resection, trauma, or selective surgery have in many cases presented insurmountable challenges to the current gold standard treatment for bone repair. The primary purpose of a tissue‐engineered scaffold is to use engineering principles to incite and promote the natural healing process of bone which does not occur in critical‐sized defects. A synthetic bone scaffold must be biocompatible, biodegradable to allow native tissue integration, and mimic the multidimensional hierarchical structure of native bone. In addition to being physically and chemically biomimetic, an ideal scaffold is capable of eluting bioactive molecules (e.g., BMPs, TGF‐βs, etc., to accelerate extracellular matrix production and tissue integration) or drugs (e.g., antibiotics, cisplatin, etc., to prevent undesired biological response such as sepsis or cancer recurrence) in a temporally and spatially controlled manner. Various biomaterials including ceramics, metals, polymers, and composites have been investigated for their potential as bone scaffold materials. However, due to their tunable physiochemical properties, biocompatibility, and controllable biodegradability, polymers have emerged as the principal material in bone tissue engineering. This article briefly reviews the physiological and anatomical characteristics of native bone, describes key technologies in mimicking the physical and chemical environment of bone using synthetic materials, and provides an overview of local drug delivery as it pertains to bone tissue engineering is included. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009

show abstract

“…[10,13] There are many methods to incorporate growth factors into synthetic scaffolds, such as absorbing growth factor to the scaffold, [14] blending growth factor containing microspheres into the scaffold, [10,15] or directly mixing growth factor containing protein powder into the scaffold during processing. [16,17] Adsorbing growth factor onto the scaffold has the drawback of low loading efficiencies and rapid release. Loading growth factor into microspheres can be associated with a loss in bioactivity due to harsh solvents such as methylene chloride.…”

Section: Introductionmentioning

confidence: 99%

Biodegradable elastomeric scaffolds with basic fibroblast growth factor release

Guan

Stankus

Wagner

2007

Journal of Controlled Release

149

View full text Add to dashboard Cite

Scaffolds that better approximate the mechanical properties of cardiovascular and other soft tissues might provide a more appropriate mechanical environment for tissue development or healing in vivo. An ability to induce local angiogenesis by controlled release of an angiogenic factor, such as basic fibroblast growth factor (bFGF), from a biodegradable scaffold with mechanical properties more closely approximating soft tissue could find application in a variety of settings. Toward this end biodegradable poly(ester urethane)urea (PEUU) scaffolds loaded with bFGF were fabricated by thermally induced phase separation. Scaffold morphology, mechanical properties, release kinetics, hydrolytic degradation and bioactivity of the released bFGF were assessed. The scaffolds had interconnected pores with porosities of 90% or greater and pore sizes ranging from 34-173 μm. Scaffolds had tensile strengths of 0.25-2.8 MPa and elongations at break of 81-443%. Incorporation of heparin into the scaffold increased the initial burst release of bFGF, while the initial bFGF loading content did not change release kinetics significantly. The released bFGF remained bioactive over 21 days as assessed by smooth muscle mitogenicity. Scaffolds loaded with bFGF showed slightly higher degradation rates than unloaded control scaffolds. Smooth muscle cells seeded into the scaffolds with bFGF showed higher cell densities than for control scaffolds after 7 days of culture. The bFGFreleasing PEUU scaffolds thus exhibited a combination of mechanical properties and bioactivity that might be attractive for use in cardiovascular and other soft tissue applications.

show abstract

Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering

Cited by 385 publications

References 31 publications

Osteogenesis and angiogenesis: The potential for engineering bone

Osteogenesis and angiogenesis: The potential for engineering bone

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Biodegradable elastomeric scaffolds with basic fibroblast growth factor release

Contact Info

Product

Resources

About